BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12180486)

  • 1. Alemtuzumab, the first monoclonal antibody (MAb) directed against CD52.
    Keating M; Hallek M
    Med Oncol; 2002; 19 Suppl():S1-2. PubMed ID: 12180486
    [No Abstract]   [Full Text] [Related]  

  • 2. Alemtuzumab in B-cell chronic lymphocytic leukemia.
    Shapira I; Grossbard ML
    Clin Lymphoma; 2004 Mar; 4(4):228-9. PubMed ID: 15072614
    [No Abstract]   [Full Text] [Related]  

  • 3. Alemtuzumab in chronic lymphocytic leukemia.
    James DF; Kipps TJ
    Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab: a new option for refractory chronic lymphocytic leukemia?
    Smith JA
    Cancer Pract; 2001; 9(4):211-3. PubMed ID: 11879313
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia.
    Osterborg A; Mellstedt H; Keating M
    Med Oncol; 2002; 19 Suppl():S21-6. PubMed ID: 12180488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab.
    Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
    [No Abstract]   [Full Text] [Related]  

  • 7. Progress with alemtuzumab in chronic lymphocytic leukemia: Update from the 2003 meeting of the american society of hematology.
    Lee D
    Clin Lymphoma; 2004 Mar; 4(4):217-9. PubMed ID: 15072612
    [No Abstract]   [Full Text] [Related]  

  • 8. Campath-1H for chronic lymphocytic leukemia.
    Rai KR
    Clin Lymphoma; 2002 Sep; 3(2):73-4. PubMed ID: 12435278
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
    De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
    Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disseminated molluscum contagiosum in a patient with chronic lymphocytic leukaemia after alemtuzumab.
    Pitini V; Arrigo C; Barresi G
    Br J Haematol; 2003 Nov; 123(4):565. PubMed ID: 14616955
    [No Abstract]   [Full Text] [Related]  

  • 11. Alemtuzumab for B-cell chronic lymphocytic leukemia.
    Robak T
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is alemtuzumab really the single active agent for treatment of chronic lymphocytic leukemia?
    Oberoi SS; Abou Jawde RM
    J Clin Oncol; 2008 Dec; 26(35):5827-8; author reply 5828-9. PubMed ID: 19001335
    [No Abstract]   [Full Text] [Related]  

  • 13. Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab.
    Laurenti L; Tarnani M; Innocenti I; Savino G; Battendieri R; Larocca LM; Chiusolo P; SorĂ  F; Sica S; Efremov D; Leone G
    J Clin Oncol; 2008 Nov; 26(32):5299-301. PubMed ID: 18854557
    [No Abstract]   [Full Text] [Related]  

  • 14. Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy.
    Bolli N; Di Ianni M; Simonetti S; Cerroni L; Liso A; Falini B; Tabilio A
    Lancet Oncol; 2004 Jan; 5(1):64-5. PubMed ID: 14700612
    [No Abstract]   [Full Text] [Related]  

  • 15. Alemtuzumab for treatment of lymphoproliferative disorders.
    Haematologica; 2004 Dec; 89(12):1419. PubMed ID: 15590389
    [No Abstract]   [Full Text] [Related]  

  • 16. The emerging role of alemtuzumab in chronic lymphocytic leukemia.
    Nabhan C
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):115-21. PubMed ID: 16231849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
    Grey M
    Br J Haematol; 2008 Jul; 142(1):1. PubMed ID: 18477054
    [No Abstract]   [Full Text] [Related]  

  • 18. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
    Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
    Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.
    Siders WM; Shields J; Garron C; Hu Y; Boutin P; Shankara S; Weber W; Roberts B; Kaplan JM
    Leuk Lymphoma; 2010 Jul; 51(7):1293-304. PubMed ID: 20377308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the use of alemtuzumab in CLL.
    Stilgenbauer S
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):23-4. PubMed ID: 18322437
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.